$DCTH Banking On Dilutive MetastasisAlthough FDA approval is a promising sign to invest in biotech stocks, that may not be the case with Delcath Systems, Inc. (NASDAQ: DCTH) whose treatment for a form of metastatic melanoma – Heozato Kit – was recently approved by the FDA. The promising biotech company is suffering from high cash burn